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resumo 
 
 
 
 
A Polineuropatia amiloidótica familiar (FAP) ou paramiloidose é uma 
doença neurodegenerativa autossómica dominante com início na vida 
adulta sendo caracterizada pela deposição da proteína mutada na forma 
de substância amilóide. A FAP é devida a uma mutação pontual no gene 
transtirretina (TTR) e até agora mais de 100 mutações amiloidogénicas 
foram descritas neste gene. A FAP apresenta uma grande variação na 
idade de início (AO) (19-82 anos, nos casos portugueses) e a mutação 
V30M pode segregar através de várias gerações de portadores 
assintomáticos, antes de se expressar num probando. No entanto, este 
efeito protetor pode desaparecer numa única geração, com os filhos de 
casos tardios a apresentarem um início precoce. 
A mutação V30M não explica por si só os sintomas e a variabilidade da 
AO observada dentro de uma mesma família.  
O nosso objetivo neste trabalho foi identificar fatores genéticos 
associados com a variabilidade da AO e a penetrância reduzida. De 
modo a cumprir este objetivo genotipámos 230 doentes, por 
sequenciação automática, para identificar possíveis modificadores 
genéticos dentro do locus da TTR. Após a genotipagem, investigamos 
uma possível associação dos SNPs encontrados com a AO e realizamos 
uma intensiva análise in silico de modo a perceber uma possível 
regulação da expressão génica. 
Apesar de não termos encontrado nenhuma associação entre os SNPs 
e a AO, encontrámos resultados não descritos e muito interessantes na 
análise in silico dado termos observado algumas alterações a nível do 
mecanismo de splicing, ligação de fatores de transcrição e ligação de 
miRNAs. Todos estes mecanismos quando alterados podem levar à 
desregulação da expressão do gene, o que pode ter um impacto na AO 
e variabilidade fenotípica.  
Estes mecanismos hipotéticos da regulação da expressão génica no 
gene da TTR podem ser úteis para no futuro serem aplicados como 
potenciais alvos terapêuticos, beneficiando o aconselhamento genético 
e o follow-up dos portadores da mutação. 
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abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Familial amyloid polyneuropathy (FAP) or paramiloidosis is an autosomal 
dominant neurodegenerative disease with onset on adult age that is 
characterized by mutated protein deposition in the form of amyloid 
substance. FAP is due to a point alteration in the transthyretin (TTR) gene 
and until now more than 100 amyloidogenic mutations have been 
described in TTR gene. FAP shows a wide variation in age-at-onset (AO) 
(19-82 years, in Portuguese cases) and the V30M mutation often runs 
through several generation of asymptomatic carriers, before expressing 
in a proband, but the protective effect disappear in a single generation, 
with offspring of late-onset cases having early onset. 
V30M mutation does not explain alone the symptoms and AO variability 
of the disease observed in the same family. Our aim in this study was to 
identify genetic factors associated with AO variability and reduced 
penetrance which can have important clinical implications. 
To accomplish this we genotyped 230 individuals, using a direct-
automated sequencing approach in order to identify possible genetic 
modifiers within the TTR locus. After genotyping, we assessed a putative 
association of the SNPs found with AO and an intensive in silico analysis 
was performed in order to understand a possible regulation of gene 
expression. 
Although we did not find any significant association between SNPs and 
AO, we found very interesting and unreported results in the in silico 
analysis since we observed some alterations in the mechanism of 
splicing, transcription factors binding and miRNAs binding. All of these 
mechanisms when altered can lead to dysregulation of gene expression, 
which can have an impact in AO and phenotypic variability. 
These putative mechanisms of regulation of gene expression within the 
TTR gene could be used in the future as potential therapeutical targets, 
and could improve genetic counselling and follow-up of mutation carriers. 
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ABBREVIATIONS 
 
AO Age-at-onset 
APCS  Amyloid P component, serum 
CNS Central Nervous System 
CV  Consensus value 
ddNTP  Dideoxynucleotide 
ESE  Exonic splicing enhancer 
FAP Familial Amyloid Polyneuropathy 
FUS Fused in sarcoma 
Fw Foward 
IL-1β  Interleukin 1β 
HSF  Human Splicing Finding 
IL-1β Interleukine-1β 
iNOS  inducible Nitric Oxide Synthase 
M-CSF Macrophage colony-stimulating factor 
MAPT Microtubule-associated protein tau 
miRNA  microRNA 
MS Matrix score 
NF-kB Nuclear factor kappa B 
PCR Polymerase chain reaction 
PNS  Peripheral Nervous System 
RAGE  Receptor for Advanced Glycation Endproducts 
RBP Retinol binding protein 
RFLP Restriction fragment length polymorphism  
Rv Reverse 
SC Schwann cell 
SNP Single nucleotide polymorphism 
SSCP Single stranded conformational polymorphism  
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SR Serine/arginine-rich 
TF Transcription factor 
TFB Transcription factor binding 
TFBS Transcription factor binding site 
TNF-α Tumor Necrosis Factor α 
TTR Transthyretin  
UTR Untranslated region 
WT Wild type 
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1.1. Familial Amyloid Polyneuropathy (FAP) 
 
Paramiloidosis or FAP is an autosomal dominant neurodegenerative disease 
characterized by mutated protein deposition in the form of amyloid substance (Andrade 
1952, Becker, Antunes et al. 1964).  There are three main types of FAP, defined according 
to the precursor protein of amyloid: transthyretin (TTR), apolipoprotein A-1 and gelsolin 
(Plante-Bordeneuve and Said 2011). 
FAP was for the first time described in Portugal by Corino de Andrade in 1952 in patients 
originated from Póvoa de Varzim (Andrade 1952, Becker, Antunes et al. 1964). The disorder 
was subsequently recognized in Japan (1968) and Sweden (1976) (Andersson 1976, Saraiva, 
Birken et al. 1984)(Figure 1).  
Later, the most common TTR mutation, a substitution of a valine for a methionine at 
position 30 in TTR (V30M) has been identified in Portuguese, Swedish and Japanese families 
(Tawara, Nakazato et al. 1983, Dwulet and Benson 1984, Saraiva, Birken et al. 1984, de 
Carvalho, Moreira et al. 2000), and until now more than 100 amyloidogenic mutations have 
been described in TTR gene (Araki and Ando 2010). 
FAP TTR affects 1/100,000 people, but the number varies by country (Figure 1). In Póvoa 
de Varzim, the prevalence of TTR V30M is about 1/1,000 (Sousa, Andersson et al. 1993, 
Sousa, Coelho et al. 1995, Benson 2000). 
 
 
Figure 1: World distribution of FAP TTR. Data from Plante-Bordeneuve and Said 2011. 
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The V30M TTR mutation leads to disease with a variable degree of penetrance and age 
of disease onset (Sousa, Coelho et al. 1995).  
In Portugal, the penetrance is high (80%), genetic anticipation is noted and clinical 
symptoms typically occurs before age of 40 and consist of progressive and severe sensory, 
autonomic and motor polyneuropathy, that lead to death within 10-20 years without 
treatment (Coutinho P. 1980, Sousa, Coelho et al. 1995). 
  
1.2. The hallmark of FAP 
 
1.2.1. Transthyretin  
 
TTR is a 127-residue polypeptide chain with approximate 14 kDa found in the 
bloodstream that assembles to form a homotetrameric protein with a β-sheet secondary 
structure. It is mainly synthesized in liver, although a small amount is produced by the 
retinal cells and choroid plexus (Saraiva 2001). 
TTR circulates in soluble form in the plasma and cerebrospinal fluid and transports 
thyroxin and retinol, which explain its name: TransThyRetin (Raz and Goodman 1969, 
Fleming, Nunes et al. 2009).  
 
1.2.2. Deposition of amyloid in the peripheral nervous system 
 
The TTR gene (in chromosome 18q11.2-12) is small and contains four exons. The 
pathogenic mutations lead to amino acid substitutions that result in conformational 
changes in the protein that lead to weaker interactions between the TTR tetramers, 
decrease their stability and increase their dissociation into monomers, which self-assemble 
in the extracellular space, leading to the formation of non-fibrillar soluble oligomers and 
protofibrils that assemble to create insoluble amyloid fibrils deposits in peripheral and 
autonomic nerve tissues in later stages of disease (Andrade 1952, Merlini and Bellotti 2003, 
Hou, Aguilar et al. 2007). These deposits have both normal and mutant TTR, what explains 
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the progression of amyloid deposits even after liver transplantation (Yazaki, Tokuda et al. 
2000, Tsuchiya, Yazaki et al. 2008, Liepnieks, Zhang et al. 2010) (Figure 2 and Figure 3). 
 
Figure 2: Schematic representation of amyloid fibrils 
formation and deposition (normal TTR monomers, in light 
blue, and mutant TTR monomers, in dark blue). 
 
 
Figure 3: Pathology of early and late stages of FAP TTR – (A) Section of a sural nerve biopsy from a patient carrying 
V30M mutation with early symptoms of polyneuropathy, showing the presence of small amyloid deposits (arrows) and 
the preservation of larger myelinated fibres (arrowheads). (B) Sural nerve biopsy specimen from a patient carrying 
V30M mutation at a late stage of the disease. At this stage, endoneurial blood vessels are often invaded and destroyed 
by amyloid deposits (arrows), large myelinated fibres disappear and large endoneurial amyloid deposits are seen. 
Adapted from Plante-Bordeneuve and Said 2011. 
 
 
a B A B 
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1.3. FAP pathology and pathophysiology 
 
Several theories have been proposed to explain FAP pathology (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of pathological hypothesis for FAP (SC-Schwann cells; RAGE-receptor for advanced 
glycation end products). 
 
TTR fibrils are diffusely distributed in the peripheral nervous system (PNS) of FAP 
patients, involving peripheral nerves, nerve trunks, plexuses and ganglia. In peripheral 
nerves, the accumulation of amyloid is prominent in the endoneurium (Figure 5), Schwann 
cells (SC), collagen fibrils and around nerve blood vessels. At the onset, axonal degeneration 
occurs in the unmyelinated and low diameter myelinated fibers, with loss of pain sensation. 
As the disease progresses heavy myelinated fibers are also affected (Dyck and Lambert 
1969, Said 2003, Said and Plante-Bordeneuve 2009).  
FAP 
Amyloid deposits TTR non-fibrillar aggregates 
1. Sensory and sympathetic 
neurons lesions 
2. Compression of the nervous 
tissue by amyloid deposits 
3. Ischemia secondary to lesions 
caused by perivascular amyloid 
RAGE engagement 
Pro-inflammatory response 
Oxidative stress 
SC-axons interactions distortion 
Apoptosis 
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Figure 5: Amyloid deposits in the endoneurium in FAP TTR – 
Congo red-stained amyloid deposits (arrows) in a longitudinal 
section of a paraffin-embedded nerve biopsy specimen. Adapted 
from Plante-Bordeneuve and Said 2011. 
 
Several hypotheses have been raised based on pathological features of the disease, 
including amyloid deposition, to explain the neurodegeneration: 
1. Sensory and sympathetic neurons lesions 
When in contact with amyloid fibrils, SC basal lamina disappears and is followed 
by cytoplasmatic degenerative changes. The susceptibility of SCs to amyloid deposits 
can explain the early loss of unmyelinated fibres, because each SC harbours several 
unmyelinated fibres, but in the case of myelinated fibres, each SC harbours only one 
myelinated fibre. SCs destruction accounts for unmyelinated fibres and small 
myelinated fibres degeneration because they are responsible for their nutritional 
support (Said 2003, Said and Plante-Bordeneuve 2009).  
2. Compression of the nervous tissue by amyloid deposits 
Amyloid deposits physically displace elements of peripheral nerves, resulting in 
neuronal loss. This hypothesis of FAP pathogenesis argue that nerve fiber 
degeneration results from compression by amyloid deposits and accumulation of 
amyloid fibrils in specific areas lead to focal manifestations. However, this view 
cannot explain the diffuse depletion of nerve fibres that occurs even though amyloid 
deposits are focal and a cause-effect relationship between amyloid deposition and 
neurodegeneration was never clearly demonstrated (Dyck and Lambert 1969, 
Thomas and King 1974, Said, Ropert et al. 1984).  
3. Ischemia secondary to lesions caused by perivascular amyloid 
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Interstitial edema in the endoneurium associated with amyloid deposition in 
blood vessels and altered vascular permeability was proposed to induce ischemia in 
nerve fibers, causing the progressive polyneuropathy in FAP (Hanyu, Ikeda et al. 
1989, Fujimura, Lacroix et al. 1991). However, the destruction of blood vessels walls 
by amyloid deposits and occlusion of the lumen are seen only in severely affected 
cases, making a role of nerve ischemia unlikely (Said 2003, Said and Plante-
Bordeneuve 2009).  
The lack of evidence of the cause-effect relationship between amyloid deposition and 
neurodegeneration suggests the important role of other factors, including non-fibrillar TTR 
aggregates toxicity and extracellular matrix changes (Sousa and Saraiva 2003). 
It has been demonstrated that TTR non-fibrillar aggregates are toxic to cells and capable 
of induce neurodegenerative changes, while mature TTR fibrils present in later stages of 
FAP are unable to cause cellular damage (Sousa, Cardoso et al. 2001). The non-fibrillar 
aggregates cytotoxicity is due to their ability to induce neuronal inflammatory response by 
releasing pro-inflammatory cytokines (Tumor Necrosis Factor α - TNF-α, macrophage 
colony-stimulating factor – M-CSF, Interleukin 1β - IL-1β)  and oxidative stress due to 
enhanced expression of inducible Nitric Oxide Synthase (iNOS)  that can lead to neuronal 
death (Sousa and Saraiva 2003). 
In FAP patients, SC-axon interactions are affected by small TTR non-fibrillar toxic 
aggregates. These interactions are maintained by collagen fibrils and a functional basement 
membrane. These two elements are distorted in FAP by non-fibrillar aggregates. The 
normal response to this distortion is the increased trophic factors expression. However in 
FAP patients nerve biopsies, there were no changes in neurotrophins expression when 
compared with control nerve biopsies. The consequent lack of neurotrophins might be 
relevant for neurodegeneration and cell death (Sousa, Du Yan et al. 2001). 
Besides those hypotheses, it has been suggested that amyloidogenic molecules might 
disturb cellular properties by interacting with cellular receptors, such as receptor for 
advanced glycation end products (RAGE) – figure 4. RAGE is a member of the 
immunoglobulin superfamily with a broad range of ligands, including several amyloid-
associated macromolecules (Bucciarelli, Wendt et al. 2002). The receptor activation by TTR 
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aggregates activates signaling cascades, resulting in expression of NF-kB and other 
mediators involved in FAP neurodegeneration (Sousa, Du Yan et al. 2001). 
 
1.4. Phenotypic variability 
 
FAP shows a wide variation in age-at-onset (AO) (19-82 years, in Portuguese cases) in 
families from Portugal, Sweden and Japan, with more and more late-onset cases verified in 
Portugal and several aged-asymptomatic gene carriers, up to 95 years, identified. Late-
onset cases and aged-asymptomatic carriers aggregate in families, and that, as in Sweden, 
isolated cases with late-AO often descend from aged-asymptomatic carriers (Lobato L. 
1988, Drugge, Andersson et al. 1993, Sousa, Coelho et al. 1995, Tashima, Ando et al. 1995). 
The V30M mutation often runs through several generation of asymptomatic carriers, 
before expressing in a proband, but the protective effect disappear in a single generation, 
with offspring of late-onset cases having early onset (Figure 6). In Portugal, it was observed 
that offspring may anticipate up to 40 years in respect to their affected parent. That 
anticipation was shown in 926 Portuguese parent-offspring pairs (Lemos, Coelho et al. 
2014). It was also observed that 40% of probands had no affected parent at the time of 
their diagnosis: onset in the transmitting parent was only after (and with a later AO). These 
probands had later onset (45.1 years) than those descending from one affected parent 
(31.2 years) (Coelho, Sousa et al. 1994).  
 
 
 
 
 
 
 
 
 Figure 6: Portuguese family, as an example of 
the marked decrease in AO (anticipation) 
throughout three generations. 
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However, factors and mechanisms involved in this phenotypic variation remain largely 
unknown (Soares, Buxbaum et al. 1999). Although environmental factors cannot be 
completely ruled out, the fact is that a large variation may still be found within a single 
geographical area and, above all, within the same family. The intra-familial variability raised 
the hypothesis of a closely linked genetic modifier.  
The hypothesis of trinucleotide repeats related with AO variability was analysed for 10 
different trinucleotide repeats in 9 parent-offspring pairs and no differences were found 
(Soares, Buxbaum et al. 1999). 
Candidate genes were also studied to find common variants that could be related with 
V30M and AO. Possible interactions between loci seemed to contribute more to the 
observed differences in AO, than a single-locus effect. In early-onset patients, the amyloid 
P component, serum (APCS) gene showed a modifier effect, while in late-onset patients, 
one variant in APCS and two variants in retinol-binding protein (RBP) seemed to be involved 
(Soares, Coelho et al. 2005). 
Differences in penetrance according to gender of the transmitting parent and a parent-
of-origin effect were also found. Mother-son pairs showed larger anticipation while father-
daughter pairs showed only a residual anticipation (Lemos, Coelho et al. 2014).  The 
observation that the genetic anticipation is significantly higher when the mutation is 
inherited from the mother raised two hypothesis: the difference in the expression of the 
mutated allele according to the gender of the parent who transmitted the mutation can be 
due to an imprinting phenomenon; or the difference in penetrance according to the gender 
of the transmitting parent could be attributed to a modifier effect of a mitochondrial DNA 
polymorphism on the expression of the TTR mutation (Hellman, Alarcon et al. 2008, Bonaiti, 
Alarcon et al. 2009, Bonaiti, Olsson et al. 2010). A study was performed to test the last 
hypothesis and it was shown that a mitochondrial polymorphism effect was sufficient to 
explain the observed difference in penetrance according to gender of the transmitting 
parent in the Portuguese sample, but the same was not observed for the Swedish sample, 
so the possibility of several loci involved was hypothesized (Bonaiti, Olsson et al. 2010). 
A study was performed to analyze the haplotype effect on AO differences. It was 
suggested that the onset of symptoms of FAP V30M may be modulated by an interval 
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downstream of TTR on the accompanying non carrier chromosome, but not by the 
immediately 5’ and 3’-flanking sequences of TTR gene (Soares, Coelho et al. 2004). 
Other modifier factors involved in phenotypic variation of FAP V30M in study are the 
TTR gene methylation pattern and the cis-regulatory elements in TTR gene that may 
modulate TTR function or encode amino acid residues that change the amyloidogenic 
propensity of monomers, such as Thr119Met that has a protective effect on 
amyloidogenesis in individuals with V30M mutation (Longo Alves, Hays et al. 1997, 
Hammarstrom, Schneider et al. 2001). 
Besides the phenotypic variability between V30M individuals, some mutations are 
associated with unique phenotypes of familial TTR, such as Val122Ile and cardiac 
manifestations and Leu12Pro and leptomeningeal manifestations (Jacobson, Pastore et al. 
1997, Petersen, Goren et al. 1997, Yamashita, Hamidi Asl et al. 2005, Hellman, Alarcon et 
al. 2008). 
 
1.5. Clinical symptoms 
 
In FAP patients with Portuguese origin, heterogeneity in AO and progression of 
symptoms was observed. In patients with early-onset presentation, associated with disease 
focus, the deterioration is fast, due to autonomic dysfunction and rapid progression of the 
sensory-motor deficit. However, in patients with late-onset FAP, not associated with the 
main clusters, polyneuropathy progression is slower, sometimes with cardiac involvement 
and less autonomic dysfunction (Plante-Bordeneuve and Said 2011).  
 
1.5.1. Length-dependent sensory-motor polyneuropathy 
 
Initially, patients have discomfort in the feet, like numbness and spontaneous pain, and 
impaired thermal and pain sensation are detected at clinical examination. At this stage, 
muscle strength, tendon reflexes, light touch sensation and proprioception are preserved, 
which points to unmyelinated and small myelinated fibers involvement.  
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With the progress of the disease, thermal and pain sensation loss extended above the 
ankle level bilaterally and light touch is impaired distally. The neurological deficit becomes 
worst with sensory loss up the legs, loss of deep sensations and motor impairment, caused 
by involvement of larger sensory and motor nerve fibers. 
A few years after symptoms onset, the sensory deficit extends to the upper limbs and 
anterior trunk, and walking becomes increasingly difficult. At this stage, weight loss and 
muscle wasting are present (Dyck and Lambert 1969, Thomas and King 1974, Said, Ropert 
et al. 1984). 
 
1.5.2. Focal manifestations of sensory-motor neuropathy 
 
The deposition of amyloid in PNS can lead to local accumulation and induces focal nerves 
lesion, like carpal tunnel syndrome. This syndrome is a common, early and non-specific 
symptom of FAP that tend to be more severe in FAP patients than in idiopathic carpal 
tunnel syndrome patients, because the amyloid deposits are associated with nerve 
entrapment (Koike, Morozumi et al. 2009). 
 
1.5.3. Autonomic dysfunction 
 
Autonomic neuropathy is present in most people with early-onset FAP, but it is less 
frequent in late-onset FAP (Plante-Bordeneuve and Said 2011).  
The autonomic disturbance involves cardio-circulatory, gastrointestinal and 
genitourinary systems (Andrade 1952, Plante-Bordeneuve and Said 2011). Cardio-
circulatory dysfunction leads to orthostatic hypotension, with fatigue, blurred vision and 
dizziness (Andrade 1952, Plante-Bordeneuve and Said 2011). Gastrointestinal 
manifestations include: diarrhea, constipation, or both alternately, gastroparesis, 
hypomobility and postprandial vomiting (Andrade 1952, Ikeda, Makishita et al. 1982, 
Plante-Bordeneuve and Said 2011). These manifestations result from amyloid deposition in 
the stomach, degeneration of intrinsic autonomic nerves and decrease of duodenal 
endocrine cell content (Ikeda, Makishita et al. 1982). Genitourinary symptoms include 
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dysuria and urinary retention, which occur in a later stage of FAP, and erectile dysfunction 
in men, an early feature of FAP (Andrade 1952, Plante-Bordeneuve and Said 2011). 
 
1.5.4. Cardiac manifestations  
 
Cardiac impairment is observed in about 80% of the patients with FAP TTR, and it can be 
exclusive in some cases. Progressive amyloid deposition can lead to structural cardiac 
disturbances, including restrictive cardiomyopathy (Suhr, Lindqvist et al. 2006, Hornsten, 
Pennlert et al. 2010). Cardiac conduction disturbances, including arrhythmias and severe 
conduction disorders, are due to amyloid infiltration of the cardiac conduction system 
(Bergfeldt, Olofsson et al. 1985).  
Val122Ile mutation can lead to isolated cardiac involvement, usually with late onset. 
Approximately 4% of African Americans are heterozygous for Val122Ile, which explains the 
observation that in older individuals in the United States, cardiac amyloidosis is four times 
more common among African American (Jacobson, Pastore et al. 1997, Yamashita, Hamidi 
Asl et al. 2005). 
 
1.5.5. Ocular manifestations 
 
Ocular disturbances, including vitreous opacities, scalloped pupils and trabecular 
obstruction, are reported in about 10% of the cases of FAP TTR (Ando, Ando et al. 1997). 
Abnormal pupillar reactions to light and scalloped pupils due to involvement of ciliary 
nerves by amyloid deposits have been verified (Andrade 1952). 
 
1.5.6. Central Nervous System involvement 
 
Central Nervous System (CNS) symptoms in V30M TTR amyloidosis are rare despite the 
occurrence of leptomeningeal amyloid deposition (Said and Plante-Bordeneuve 2009), 
however some TTR mutations are associated with oculoleptomeningeal amyloidosis 
(Goren, Steinberg et al. 1980, Brett, Persey et al. 1999). These individuals have vitreous 
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amyloid deposits and CNS manifestations including dementia, psychosis, visual 
impairment, headache, seizures, motor paresis, ataxia, hydrocephalus or intracranial 
hemorrhage (Petersen, Goren et al. 1997, Brett, Persey et al. 1999). 
 
1.5.7. Renal Manifestations 
 
Renal involvement, including proteinuria and progressive renal failure, occurs in one-
third of the Portuguese cases (Lobato, Beirao et al. 2004). These manifestations are 
correlated with heavy amyloid deposition in the glomeruli, arterioles, and medium vessels, 
but not with deposition in medullary tissues (Lobato, Beirao et al. 1998). The progression 
and severity of nephropathy are not correlated with the degree of polyneuropathy 
(Takahashi, Sakashita et al. 1997, Misu, Hattori et al. 1999, Oguchi, Takei et al. 2006). 
 
1.6. Diagnosis 
 
On clinical examination, signs of small myelinated fibres neuropathy or autonomic 
neuropathy, family history and geographic origin should be valorized (Coelho T 1997).  
Temperature, light touch, proprioception, vibratory and pain sensation must be tested, 
like muscular strength and tendon reflexes. Sensory and motor deficit must be graded and 
recorded for posterior comparison (Plante-Bordeneuve and Said 2011). 
In case of association of a sensory-motor and autonomic polyneuropathy with a family 
history, amyloid deposits in tissue biopsy is not mandatory, but DNA testing is essential 
(Figure 7) (Plante-Bordeneuve and Said 2011). 
In patients without a known family history of amyloidosis and with a progressive axonal 
polyneuropathy of unknown origin, a biopsy of an affected organ, including nerve, 
abdominal fat, salivary gland or muscle specimens, could be done to show the presence of 
extracellular amyloid deposits in the endoneurial space or to differentiate amyloid 
polyneuropathy from other conditions, like chronic inflammatory demyelinating 
polyneuropathy, and to direct the DNA testing (Figure 7) (Kanda, Goodman et al. 1974, 
Koike, Hashimoto et al. 2011, Plante-Bordeneuve and Said 2011, Gustafsson, Ihse et al. 
2012). 
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Congo red tinctorial affinity or thioflavin T along with a characteristic yellow-green 
birefringence under polarized light are characteristic of amyloid deposits, but they cannot 
confirm the type of amyloid. Biopsy products of FAP TTR visualized by electron microscopy 
could show the fibrillar aspect of amyloid deposits, made up of unbranched fibrils of several 
lengths, with diameters ranging from 7 to 10 nm and parallel dense borders (Inoue, 
Kuroiwa et al. 1998, Plante-Bordeneuve and Said 2011). To identify the amyloid type, mass-
spectroscopy based proteomic analysis or immunolabelling with anti-TTR antibody can be 
used, but they do not specify the TTR mutation, therefore DNA testing remains mandatory 
(Plante-Bordeneuve and Said 2011).  
Molecular genetics-based methods used for DNA testing are restriction fragment length 
polymorphism (RFLP), single stranded conformational polymorphism (SSCP) and DNA 
sequencing (Pinho e Costa 2006).  Due to FAP significant allelic heterogeneity, sequencing 
of the TTR gene entire coding regions is always recommended (Mario Nuvolone 2012).  
When the diagnosis of FAP TTR has been achieved, extra-neurologic investigations, 
including ophthalmologic, nephrologic and cardiologic assessment, should be performed 
to evaluate the systemic involvement (Mario Nuvolone 2012). 
 Patients in disease focus 
 Patients with family 
history of FAP 
 Early AO 
 
 Isolated patients 
 Patients with no family 
history of FAP 
 Late AO 
Impairment of pain and 
temperature sensations in 
feet, often with autonomic 
dysfunction 
Nerve length dependent 
progressive sensory-motor 
polyneuropathy, often with 
cardiac involvement 
DNA testing to confirm 
amyloidogenic TTR mutation 
Tissue biopsy to show amyloid 
deposits 
Figure 7: Clinical presentation and diagnosis of early- onset and late-onset of FAP TTR. 
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1.7. Treatment 
 
A multidisciplinary approach is required to alleviate the symptoms of FAP TTR patients 
and to prevent complications. Besides symptomatic treatment, etiologic treatment is 
needed to stop or inhibit the cascade of events involved in TTR production and 
amyloidogenesis (Figure 8) (Plante-Bordeneuve and Said 2011). 
 
 
SYMPTOMATIC TREATMENT 
 
 
 
 
 
 
 
 
1.7.1. Symptomatic treatment 
 
It is essential to promote positive attitude facing the disease, to find solutions to each 
problem, to stimulate an active life and to control symptoms (Coelho 2006, Plante-
Bordeneuve and Said 2011). 
The multiple symptoms of FAP requires a multidisciplinary team to perform this type of 
intervention and to listen to the patient and to explain the mechanisms of symptoms and 
complications and the adequate adaptations (Coelho 2006). 
 
 
 
 
 Pacemaker or 
antiarrhytmic drugs 
 Dialysis and renal 
transplantation 
 Foot care to protect 
hyposensitive areas 
 Surgical decompression 
in carpal tunnel 
syndrome 
+ 
Figure 8: Symptomatic treatment options and strategies in potential molecular therapies 
for FAP TTR.  
SYMPTOMATIC TREATMENT ETIOLOGIC TREATMENT 
 Pacemaker or 
antiarrhytmic drugs 
 Dialysis and renal 
transplantation 
 Foot care to protect 
hyposensitive areas 
 Surgical decompression in 
carpal tunnel syndrome 
 
 Inhibition of synthesis of 
mutant TTR 
 Stabilization of mutant TTR 
 Inhibition of aggregation of 
amyloidogenic 
intermediates 
 
+ 
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1.7.2. Ethiologic treatment 
 
1.7.2.1.  Liver transplantation 
 
The aim of the liver transplantation is to avoid the formation of additional deposits by 
removing the main source of mutated TTR (Holmgren, Steen et al. 1991). The surgery is 
beneficial in young patients with V30M mutation and symptomatic FAP TTR (Okamoto, 
Wixner et al. 2009, Plante-Bordeneuve and Said 2011). By contrast, liver transplantation is 
not an option for asymptomatic mutation carriers because of incomplete penetrance and 
for patients who have disease onset after 50 years, whose survival does not differ from 
non-grafted controls (Hornsten, Wiklund et al. 2004, Yamamoto, Wilczek et al. 2007). 
Heart and nerve involvement might progress even after liver transplantation because of 
wild-type TTR continued deposition on pre-existing amyloid deposits and continued 
deposition in nerves of mutated TTR secreted in small amount by choroid plexus (Ando, 
Terazaki et al. 2004, Liepnieks and Benson 2007, Yazaki, Mitsuhashi et al. 2007, Liepnieks, 
Zhang et al. 2010). Therefore liver transplantation does not prevent cardiac amyloidosis 
progression (Okamoto, Hornsten et al. 2011). 
Another aspect of liver transplantation is that it has no effect on ocular or CNS 
manifestations of amyloidosis because of continued synthesis of mutated TTR by retinal 
epithelial cells and the choroid plexus (Hara, Kawaji et al. 2010).  
 
1.7.2.2. TTR stabilizers  
 
TTR stabilizers act as pharmacologic chaperones of TTR that bind specifically to the 
tetramers and halt the amyloid process by preventing tetramer dissociation into monomers 
(Miroy, Lai et al. 1996, Peterson, Klabunde et al. 1998, Baures, Oza et al. 1999).  Two drugs, 
diflunisal and tafamidis meglumine have entered into clinical trials.  
Diflunisal, a non-steroidal anti-inflammatory agent, provides a rare example of 
repurposing old drugs for new indications. A double-blind placebo-controlled study 
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revealed that the use of diflunisal compared with placebo for 2 years reduced the rate of 
neurological impairment progression and preserved quality of life (Berk, Suhr et al. 2013).  
Tafamidis became the first drug to be approved for the treatment of TTR-FAP. The safety 
and efficacy of tafamidis were evaluated over 30 months and it was safe and well tolerated 
over this time. The effect of tafamidis in slowing neurologic progression and preserving 
quality of life was sustained over the 30 months, but treatment benefits were greater when 
the treatment begun earlier (Coelho, Maia et al. 2013). However, Tafamidis has only 
demonstrated efficacy in 60% of patients, while in 40%, disease has continued to progress. 
A large number of patients now have an alternative to transplantation and a new approach 
to a longer and a better quality of life. But an unacceptably large number will not benefit 
from this therapy and the reason is unknown and the ability to predict response is not yet 
possible.  
 
1.7.2.3.  Targeted gene repair 
 
The correction of a pathogenic mutation by DNA oligonucleotides has been studied in 
order to apply to mutated TTR allele repair (Cole-Strauss, Yoon et al. 1996). Intrahepatic 
injection of single-stranded oligonucleotides led to a gene conversion of 8-9% at both 
messenger RNA and protein level (Nakamura, Ando et al. 2004). Although this approach 
requires further investigation, it could be essential in the treatment of asymptomatic 
carriers, especially in areas with high penetrance of pathogenic mutations, and an 
alternative to liver transplantation (Propsting, Kubicka et al. 2000). 
 
1.7.2.4.  Suppression of mutant transthyretin messenger ribonucleic  acid 
 
Downregulation of TTR mRNA could be a strategy alternative to the gene therapy. The 
first is transient and rely on continuous administration of the knockdown agent (ribozymes, 
small interfering RNA or antisense oligonucleotide), while the last one can be permanent 
(Mario Nuvolone 2012). 
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Recently, small interfering RNA molecules, like patisiran (ALN-TTR02), have been 
developed. Those molecules can silence specific mRNA thereby preventing disease-causing 
proteins from being made (Mario Nuvolone 2012). Phase 1 study showed that the mean 
reductions in TTR levels in healthy volunteers ranged from 83.4 to 86.8% (Coelho, Adams 
et al. 2013). 
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Familial amyloid polyneuropathy or paramiloidosis is an autosomal dominant 
neurodegenerative disease with onset on adult age that is characterized by mutated 
protein deposition in the form of amyloid substance.  
The most common form of the disease is caused by V30M mutation in TTR gene but 
more than 100 amyloidogenic mutations have been described in TTR. 
TTR gene mutations do not explain alone the symptoms and AO variability of the disease 
observed in the same family. In some cases, V30M mutation cross several asymptomatic 
carriers generations in the same family, however this protector effect can disappear in 
other generation. Thus lead to a classic presentation of the disease with early onset on 
offspring of late onset disease cases – genetic anticipation. 
The incomplete penetrance, the variance in AO, diverse disease progression, and 
variability in symptoms and affected organs are widely recognized in TTR mutations carriers 
and justify the need to understand the mechanisms involved in phenotypic variation of the 
disease. The identification of genetic factors associated with late onset and reduced 
penetrance can have important clinical implications. 
In this thesis, FAP families were studied to identify possible variants on TTR gene that 
may act as genetic modifiers on AO.  
Thus the specific aims of this dissertation are: 
 Construct and analyze families pedigrees to understand the variability of age 
disease onset within and between families  and disease segregation; 
 Identify variants on TTR gene that can act as genetic modifiers; 
 In silico analysis of the variants found in the TTR gene and its implications in FAP 
TTR AO and gene expression. 
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2.1. Study group 
 
The present study included 230 individuals V30M symptomatic carriers from the registry 
of the Unidade Corino de Andrade, Hospital de Santo António, which is the largest registry 
worldwide, collected and clinically characterized over 70 years. The subjects had been 
diagnosed with FAP, according to the presence of characteristic clinical features of the 
disorder and genetic testing.  Blood or saliva samples were obtained with informed consent 
and DNA was extracted by standard techniques. 
 
2.2. Sample Collection and Pedigrees Constructing 
 
Blood was collected according to standard procedures in an EDTA tube, to prevent 
coagulation. Once arrived at the laboratory, samples were immediately aliquoted and 
frozen at 4°C.   
Saliva from a negative control (healthy individuals) was collected using Oragene DNA 
Self Collection Kits (DNA Genotek, Ottowa, Canada).   
Families’ pedigrees were constructed using Cyrillic 2.1. 
 
2.3. TTR Genotyping 
 
After extraction of genomic DNA from blood, sequencing of the full coding region, the 
flanking and the regulatory regions of the TTR gene was performed. Briefly, the coding 
sequence of the entire gene was amplified by polymerase chain reaction (PCR) using four 
pairs of primers. Then the PCR products were examined by direct sequencing, with the 
same set of primers as for amplification. 
 
2.3.1. Genomic DNA extraction 
 
Genomic DNA was extracted from peripheral blood leucocytes, using the QIAamp® DNA 
Blood Mini Kit (QIAGEN™) based on manufacturer’s instructions.  
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Saliva extraction was performed using Oragene DNA Self Collection Kits (DNA Genotek, 
Ottowa, Canada) according to manufacturer’s instructions. 
 
2.3.2. DNA concentration and purity with Nanodrop 
 
In order to evaluate concentration and purity of genomic DNA extracted, 2 μL of each 
sample were analyzed, using the NanoDrop Spectrophotometer ND-1000 (Thermo 
Scientific). Purity is given by the A260/A280 ratio and concentration is expressed in μg/μL. 
 
2.3.3. Amplification of TTR gene by PCR 
 
PCR is a scientific technique to replicate DNA from a template, generating innumerous 
copies of a specific sequence from the template DNA according to the primers used. This 
technique was used to amplify TTR gene from genomic DNA of each patient, using 
HotStarTaq DNA Polymerase® (Qiagen™) and primers forward and reverse for each exon, 
with the sequences referred in (Table 1 in Appendix). An additional sample without DNA 
was also included as a control for the PCR reaction. 
Each PCR reaction was performed using a mixture of reagents referred (Table 2 in 
Appendix). 
Cycle conditions program for the denaturing, annealing and extension steps are 
indicated in Table 3 in Appendix. 
In order to test if the PCR products amplified were contaminated, QIAxcel® 
BioCalculator, an automated capillary electrophoresis system, was used. 
 
2.3.4. Purification  
 
For the purpose of remove unincorporated primers and nucleotides from amplification 
reaction, in order to prepare the sequencing reaction, purification of the PCR products with 
illustra™ Exostar™ was performed. Each reaction was performed using the components 
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referred in the following in Table 4 in Appendix.  Conditions program for the purification 
are indicated in Table 5 in Appendix. 
 
2.3.5. Sequencing 
 
Following purification, sequencing of PCR product was performed with dye terminator 
chemistry approach from Applied Biosystems™. Cycle sequencing is a method in which 
successive cycles of denaturation, annealing and extension in a thermocycler result in linear 
amplification of extension products.  
In this specific sequencing method the dyes are attached to the ddNTPs 
(dideoxynucleotides), requiring one reaction tube per sample. Each ddNTP will carry a 
different color of dye and all terminated fragments contain a dye at their 3’ end. 
Each sequencing reaction was performed using the components referred (Table 6 in 
Appendix). 
  Cycle sequencing conditions program are indicated in Table 7 in Appendix. 
Sequencing capillary electrophoresis was performed in ABI Prism 3130xl Sequencer 
analyzer (Applied Biosystems TM) and data were analyzed with SeqScape v2.6 software 
(Applied Biosystems TM). 
 
2.4. In silico analysis 
 
To predict the impact of sequence variants on TTR function, bioinformatics tools 
included in the Alamut Mutation Interpretation Software (Interactive Biosoftware, Rouen 
France) and Polyphen-2 were applied. 
In order to predict how likely a splicing change would occur as a result of the presence 
of the single nucleotide polymorphism (SNP), we used two prediction programs (ESE Finder 
and Human Splicing Finder - HSF) in Alamut Software. 
The software is-rSNP was utilized to explore the transcription factors binding (TFB) 
capacity by variant sequences. We set the significance level for the is-rSNP analysis at 0.05 
and JASPAR database was used as reference (Macintyre, Bailey et al. 2010). 
 
 
 
Familial amyloid polyneuropathy: TTR sequencing and in silico analysis 
 
 
32 
 
miRNA target sites in the 3’UTR TTR-WT were predicted by miRWalk (Dweep, Sticht et 
al. 2011). The miRWalk algorithm identifies possible miRNA binding sites up to possible 
matching on the complete sequence of 3’UTR. In addition, miRWalk compares its identified 
miRNA binding sites with the results of 8 established miRNA-target prediction programs i.e. 
DIANA-microT, miRanda, miRDB, PicTar, PITA, RNA22, RNAhybrid and 
TargetScan/TargetScanS. 
To predict whether an allele change of a 3’UTR SNPs lead to a disruption or creation of 
novel miRNA binding sites, we used PITA algorithm, taking in account the conservation and 
the differences in the alignment scores (Kertesz, Iovino et al. 2007). 
 
2.5. Statistical analysis 
 
We estimated the frequencies of the different polymorphisms found according to 
gender. To compare genotypic frequencies between early- (<40) and late-onset patients 
(≥40), a chi-square test was used. Multivariate analyses were conducted using generalized 
estimating equations (GEE) to assess the simultaneous association of the different 
polymorphisms with AO variation in FAP (as the dependent variable), using the most 
common genotype as the reference category and a multilevel approach to account for the 
non-independency among members of the same family. All statistical analyses were 
performed using IBM SPSS Statistics software (v.20). 
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3.1. Study group demographic characteristics  
 
The present study included 230 individuals V30M symptomatic carriers from the registry 
of the Unidade Corino de Andrade, Hospital de Santo António. In the early-onset group 
(before age 40, n = 151), the mean AO was 31.70 years, whereas the late-onset (after age 
40, n = 79), presented an average onset of 54.97 years. In the study, 71 females and 80 
males, with early AO, and 48 females and 31 males, with late AO were included (Table 8). 
 
Table 8: Characteristics of age and gender from study group. 
 
3.2. Searching for polymorphisms within the TTR locus 
 
After genotyping the coding and flanking regions of the TTR gene, we found in our 
sample, three polymorphisms previously undescribed: c.105A>G, in exon 2 (p.Lys35Lys), a 
silent mutation, c.200+107 T>C, in intron 2 and c.*75A>C in 3’UTR (Figure 9).  
Variable Early AO Late AO Total 
Age (years) 
Mean (±SD) 31.70 (±4.67) 54.97 (±10.16) 39.28(±13.37) 
Min-Max 20-40 41-72 20-72 
Gender 
Male n (%) 80 (53.0%) 31 (39.2%) 111 (48.3%) 
Female n (%) 71 (47.0%) 48 (60.8%) 119 (51.7%) 
Total 151 (65.7%) 79 (34.3%) 230 
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In addition, 2 known intronic (rs36204272, rs1791228), one 3’ UTR (rs62093482) and 2 
known exonic polymorphisms (rs28933981 and rs1800458) were found (Figure 10 and 11 
and Table 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Sequencing results for c.105A>G (A), c.200+107T>C (B) and c.*75A>C (C). 
A B C 
A B C 
Figure 10: Sequencing results for the intronic nucleotide polymorphisms: c.337-18G>C, rs36204272 (A); 
c.402*C>T, rs1791228 (B); and c.*261C>T, rs62093482 (C). 
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Table 9: SNPs found in TTR gene: dbSNP ID, location, predicted effect on protein and frequency in early and late AO patients. 
 
dbSNP ID Location 
NM_000371.3 
(HGVS) 
Region Effect on 
protein 
(Polyphen-2) 
Frequency on 
Early AO 
patients 
Frequency on 
Late AO 
patients 
rs1800458 c.76G>A, p.G26S Ex 2 Benign A(0.051) A(0.047) 
rs36204272 c.337-18G>C In 3 N.A. C (0.013) C(0) 
rs28933981 c.416C>T, 
p.T139M 
Ex 4 Probably 
damaging 
T(0) T(0.024) 
rs62093482 c.*261C>T 3’UTR N.A. T(0.013) T(0.012) 
rs1791228 c.*402C>T 3’ near gene N.A. T(0.525) T(0.447) 
N.A.: Non applicable. 
 
 
 
 
 
Figure 11: Sequencing results for the exonic nucleotide polymorphisms: 
c.416C>T, rs28933981 (A); and c.76G>A, rs1800458 (B). 
A B 
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3.3. Association of the SNPs found in the TTR gene and AO variation 
 
No significant differences were found either when comparing early- and late-onset 
patients or when analyzing AO as a continuous variable with the presence of SNPs in the 
TTR gene.  
 
3.4. Constructing pedigrees of FAP families 
 
In Figure 12, it is possible to observe 2 families, with a clear pattern of anticipation 
throughout the generations. These families are from Unidade Corino de Andrade, Hospital 
de Santo António. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: In these families it is possible to observe the marked anticipation 
throughout the generation. 
A 
B 
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3.5. Further analysis of putative effects of the SNPs found 
 
Our next step was to further explore possible regulatory effects of the SNPs found. The 
SNPs that can alter the splicing signals or that are within splicing motifs can be found in 
Table 10 (alterations in splice sites detected by HSF software) and in Table 11 (modifications 
of ESE (Exonic Splicing Enhancers) motifs detected by ESEfinder). 
 
Table 10: Predictions from splice sites alterations by HSF software. 
 
Tagging 
SNP 
Location Splice Sites WT CV 
Mutant 
CV 
CV 
Variation 
Location from SNP 
rs28933981 
416G>C 
(Thr139Met) 
branch 
point 
50.1 46.9 -3.2 79 nt upstream 
rs1800458 76G>A (Gly26Ser) 
donor site 81.9 71.3 -10.6 -  
acceptor 
site 
0 77 77 2 nt downstream 
acceptor 
site 
69.1 68.9 -0.2 12 nt downstream 
branch 
point 
66.7 66.5 -0.2 4 nt downstream 
branch 
point 
46.5 46.3 -0.2 5 nt downstream 
rs62093482 261C>T 
branch 
point 
46.3 43.1 -3.2 2 nt upstream 
branch 
point 
30.9 30.5 -0.4 4 nt downstream 
acceptor 
site 
71.4 70.8 -0.6 6 nt downstream 
acceptor 
site 
67.1 68.3 1.2 9 nt downstream 
acceptor 
site 
66.3 68.1 1.8 11 nt downstream 
rs1791228 402C>T 
acceptor 
site 
75.9 75.2 -0.7 4 nt downstream 
branch 
point 
44.5 37 -7.5 1 nt downstream 
branch 
point 
60.2 85 24.8 2 nt downstream 
rs36204272 18G>S donor site 68.6 0 -68.6 -  
C.V.: Consensus Value. 
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Table 11: Prediction for ESE alterations by ESEfinder software. 
 
Tagging SNP SR Protein WT MS 
Mutant 
MS 
MS 
Variation 
Location from 
SNP 
rs28933981 
SRp40 2.81 0 -2.81 6 nt upstream 
SRp55 3.89 0 -3.89 2 nt upstream 
SF2/ASF site 2.03 0 -2.03  - 
SF2/ASF (IgM-BRCA1) site 2.87 0 -2.87  - 
rs1800458 
SC35 0 2.73 2.73 6 nt upstream 
SC35 0 2.67 2.67 2 nt upstream 
SC35 3.02 2.57 -0.45 7 nt upstream 
SF2/ASF site 0 1.99 1.99 6 nt upstream 
SF2/ASF site 4.64 2.73  -1.91 4 nt upstream 
SF2/ASF (IgM-BRCA1) site 4.56 2.86 -1.70 4 nt upstream 
rs62093482 SC35 3.73 3.5 -0.23 3 nt upstream 
rs1791228 
SRp40 3.05 3.71 0.66 3 nt upstream 
SF2/ASF (IgM-BRCA1) site 2.33 2.58 0.25 1 nt upstream 
MS: Matrix Score 
 
Furthermore, non-coding variants can also create new transcription factors binding sites 
(TFBSs) that may influence TTR expression. The is-rSNP algorithm highlighted that the 
consensus motifs of TFBs are located in the regions of rs62023482 (LM70), rs1791228 
(TEAD1, LM6, and LM201) and rs36204272 (LM103) – Table 12. 
 
 
 
 
 
 
 
 
Familial amyloid polyneuropathy: TTR sequencing and in silico analysis 
 
 
41 
 
      Table 12: Transcription Factors (TFs) predicted to bind to the polymorphic sequence of TTR gene. 
 
SNP Matrix TF Adjusted p-value 
rs62093482 CN0070.1 LM70 0.01519 
rs1791228 
MA0090.1 TEAD1 0.00149 
CN0006.1 LM6 0.00645 
CN0201.1 LM201 0.01447 
rs36204272 CN0103.1 LM103 0.00979 
 
Additionally, we also found two polymorphisms in 3’UTR of TTR: rs62093482 and the 
c.*75A>C. To investigate the presence of potential miRNA target sites that might be 
affected by these polymorphisms, we analyzed wild type and polymorphic sequences of 
the TTR 3’UTR using the miRWalk database. 
In Table 13 there are the miRNA target predictions for WT allele, for polymorphic allele 
of rs62093482 and for polymorphic allele of c.*75A>C. 
 
                                                                        Table 13: miRNA target predictions. 
 
WT 
Polymorphic (T) allele of 
rs62093482 
Polymorphic (A) allele of 
c.*75A>C 
hsa-mir-200a 
hsa-mir-141 
hsa-mir-622 
hsa-mir-1279 
hsa-mir-200a 
hsa-mir-141 
hsa-mir-1250 
hsa-mir-1267 
hsa-mir-1279 
hsa-mir-138 
hsa-mir-622 
hsa-mir-200a 
hsa-mir-141 
 
mir-200a and mir-141 are the only ones that are detected by all the 8 softwares that 
predicted target sites for the WT allele. Also according to PITA, these two miRNAs have 
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putative target sites for rs62093482 and c.*75A>C, since the presence of the variants do 
not interfere with miRNA binding to the target site.  
Moreover, according to PITA, the rs62093482 also creates a putative target site to mir-
622 and mir-1279, and the polymorphic allele of c.*75A>C is a putative target site to mir-
1250, mir-1267, mir-1279, mir-138 and mir-622 (Table 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION
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FAP is an autosomal dominant neurodegenerative disease characterized by mutated 
protein deposition in the form of amyloid substance. In our study population the mutated 
protein is TTR and the more common mutation is V30M.  
The individuals are clinically well characterized by the same small group of neurologists, 
is a unique opportunity for this research. It should enable an adequate and unbiased 
selection of patients needed for this study. Our population has a reasonable number of 
individuals, however no significant differences were found when comparing early- and late-
onset patients or when analyzing AO as a continuous variable. We have to consider that 
most of polymorphisms we studied are rare, so we have to increase our population of study 
to draw conclusions about the presence of SNPs and its effect on AO of disease. 
 
3.6. In silico analysis  
 
We performed an in silico analysis of the variants found in the TTR gene and we assessed 
its implications in FAP TTR AO and gene expression, including the effect of SNPs on protein 
function, splicing activity, TF binding and miRNA binding. 
 
3.6.1. Effect on protein function  
 
In order to explore the role of the polymorphisms found in coding and non-coding 
regions we performed an intensive in silico analysis. 
We analyzed the effect of SNPs on protein function, TF binding, on splicing activity and 
in miRNA binding. 
At first, we explored the polymorphisms that were located in the coding regions of TTR 
gene to assess the variants that may have a high probability to affect protein structure and 
function.  
The polymorphism rs1800458 (c.76G>A) is frequent and leads to a substitution of a 
glycine by a serine on position 26 (Ser6). Polyphen-2 classified this SNP as benign to protein 
function, meaning that this SNP could improve TTR transport function. This SNP was already 
related with an increased TTR thyroxine-binding affinity by Fitch et al. (Fitch, Akbari et al. 
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1991) and importantly, Jacobson, D. et al had suggested that rs1800458 a neutral 
polymorphism and its relative high frequency is related to its ancient origin, being 
widespread, not showing a selective advantage (Jacobson, Alves et al. 1995). Probably 
rs1800458 is related with an improvement of TTR transport function, but without an effect 
on amyloidogenesis.  
The polymorphism rs28933981 (c.416C>T) leads to a substitution from a threonine to a 
methionine in position 139 (Thr119Met). From Polyphen-2 results, we concluded that this 
SNP is probably damaging for protein function. Alves, I. et al (Longo Alves, Hays et al. 1997) 
showed that Thr119Met and Val30Met containing tetramers are more stable than with 
only Val30Met. In this study, the carriers of the two mutations remain asymptomatic 
although they are older than the mean AO of their affected sibs, so they supported the 
theory that the stability of the TTR molecule may be an important factor to prevent 
amyloidogenesis and the Thr119Met TTR may have a protective effect on pathogenic effect 
of Val30Met (Lobato 1996). 
Our two Thr119Met carriers have a late AO, higher than the mean AO of their affected 
kindreds since they belong to a family with an early-AO. We found that Thr119Met is 
probably damaging, however it is different from assuming that this SNP affects TTR 
tetramer stability or propensity to amyloidogenicity. A polymorphism can alter TTR 
transport function and do not interfere with tetramer instability and, thus, amyloidogenic 
deposits. Our results and the findings from in silico analysis allow us to hypothesize that 
Thr119Met may interfere with transport of RBP and thyroxine, and promote TTR stability, 
subsequently inhibiting amyloidogenicity.     
More recently, Batista et al (Batista, Gianni et al. 2014) assessed the effectiveness of 
liver-directed vectors mediated gene delivery of Thr119Met TTR to reverse and prevent 
pathology in a TTR V30M transgenic mouse model.  They concluded that Met 119 can exert 
a stabilization effect in TTR heterotetramers preventing dissociation and aggregates 
formation, but do not have an impact in pre-existing TTR aggregates, so the presence of 
this variant cannot reverse the disease in older animals, although it can reduce TTR 
deposition when it is initiated at a young age.  
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It is important to think about new approaches for treatment of FAP TTR, based on this 
Thr119Met protective effect. 
 
3.6.2. Putative effect on splicing activity, TFBSs and miRNA target sites  
 
The analysis of non-coding regions of the subjects TTR gene suggests the presence of 3 
non-coding variants, possibly cis-regulatory elements of the TTR gene that modulate the 
effect of mutations on the disease phenotype. For now, only five previous studies have 
investigated the role of non-coding variants in disease pathogenesis. In 2010, Olsson et al. 
explored the effect of a SNP  (rs62093482) in TTR 3’UTR in Swedish patients carriers of 
V30M mutation and suggested that this SNP can be located in a miRNA binding site possibly 
leading to a downregulation of mutant TTR expression, which can explain the low 
penetrance and late-onset of disease in Swedish patients (Olsson, Norgren et al. 2010). 
However, in 2012, they concluded that this genetic variant did not affect TTR mRNA 
expression (Norgren, Hellman et al. 2012). A previous study on Swedish and Portuguese 
V30M carriers analyzed the coding and non-coding regions of TTR gene and its 
surroundings, proposing that TTR downstream region may modulate the onset of the 
symptoms (Soares, Coelho et al. 2004). Finally, Polimanti et al. in 2013 studied the human 
variation of TTR gene and suggested that non-coding variants have a role in determining 
phenotypic presentation in African patients, and, in 2014, they made a progress on topics 
pertaining to TTR-related amyloidosis, such as the presence of cis-regulatory elements in 
the TTR gene and its surrounding regions and the identification of modifier genes 
(Polimanti, Di Girolamo et al. 2013, Polimanti, Di Girolamo et al. 2014). 
Therefore, a possible functional role for these variants might be as regulatory SNPs, so 
they can alter the binding affinity of a TF to the DNA or modify miRNA targeting and splicing 
activity. Taking into account these data further functional studies are required. 
 Since currently many in silico tools are available we decided to assess possible particular 
effects of the variants found using more specific bioinformatic resources. 
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3.6.2.1. Splicing analysis 
 
 The analysis of alterations in splicing activity was made on coding and non-coding 
regions and, to the best of our knowledge, no further studies about alterations in splicing 
activity on V30M TTR gene were made until now. 
The SNPs identified in this study can change the splicing activity on TTR pre-mRNA. 
Splicing is part of the mRNA maturation process and according to tissue localization and 
stage of development, pre-mRNA transcripts may be differentially spliced, leading to 
several transcripts and thus different proteins can be synthesized from the same gene 
(Breitbart, Nguyen et al. 1985). An aberrant splicing may represent up to 50% of all 
mutations that lead to gene dysfunction (Maniatis and Tasic 2002). 
Splicing machinery includes auxiliary sequences, such as ESEs. These enhancers are short 
nucleotide sequences targeted by Serine/Argine-rich (SR) proteins, such as SRp40, SC35, 
SRp55 and SF2/ASF site, that promote exon definition (Cartegni, Wang et al. 2003). 
When point mutations occur in these regulatory elements they could disrupt any of first 
described sequences and could alter splicing by re-directing the spliceosome or could alter 
the binding of auxiliary factors to exonic and intronic splicing enhancers and silencers 
(Cartegni, Chew et al. 2002). HSF analysis detected several differences between WT and 
mutant sequence. The HSF algorithm defines that a strong splice site has a consensus value 
(CV) higher that 80 and a less strong site a CV raging between 70 and 80. When the CV is 
lesser than 70, the probably of having an active splice site is lower (Desmet, Hamroun et al. 
2009).  
From these reference values and the analysis of Table 10, it is important to emphasize 
some of the differences between WT and Mutant sequence splice sites. From the five SNPs 
with differences in splicing sites, three of them (rs1800458, rs1791228 and rs36204272) 
are related with significant splicing alterations. 
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We found a new acceptor site 2 nucleotides downstream rs1800458, probably an active 
splice site, with a score of 77. Related to this SNP, a donor site existent in WT sequence is 
less strong in the mutant sequence. 
The analysis showed a branch point probably inactive in the WT sequence, that is a 
strong active splice site in the presence of rs1791228. Also the presence of rs36204272 
leads to loss of a donor site probably not active in the WT sequence. 
The results from ESEfinder showed alterations that could lead to exon skipping through 
ESE inactivation in coding regions or to intron retention through ESE activation in non-
coding regions. The values from Table 11 are all potentially significant according to the 
threshold values suggested by Cartegni, L. et al. (Cartegni, Wang et al. 2003).  We also found 
a possible inactivation and creation of ESEs in two SNPs, both in the coding region. 
Disruption of four ESEs is observed for the rs28933981 and creation of three new ESEs is 
observed in rs1800458. Because they are both in the coding region, we have to consider 
that ESEs inactivation may lead to protein-disrupting effect, but there is no evidence that 
ESEs creation in coding regions lead to splicing alterations. 
The protein-disruption effect may lead to translation of a protein tagged to be degraded 
and, in the case of rs28933981 (Thr119Met) be present in the same chromosome as V30M, 
the V30M TTR levels decrease and so the fibrils formation. Maybe because of this 
mechanism, there are patients with late onset of disease. 
Antisense oligonucleotides approaches are being used in trials to treat Duchenne 
muscular dystrophy. These antisense oligonucleotides induce skipping of exons that 
contain a premature stop codon by binding to splice sites sequences and blocking access 
of splicing factors to the targeted splice sites (Lu, Mann et al. 2003, Aartsma-Rus, van Vliet 
et al. 2009, Cirak, Arechavala-Gomeza et al. 2011). 
Another study proposed the use of antisense oligonucleotides that masked splice sites 
in MAPT gene, decreasing MAPT (microtubule associated protein tau) mRNA and tau 
protein in Tauopathies (Sud, Geller et al. 2014).The same method was proposed to alleviate 
abnormal cytoplasmic FUS (fused in sarcoma) accumulation in amyotrophic lateral sclerosis 
(Zhou, Liu et al. 2013).  
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We can hypothesized the possibility of using antisense oligonucleotides to mask splice 
sites in V30M TTR gene in heterozygotes patients, to produce a protein tagged to be 
degraded and thus inhibiting mutant protein formation. 
 
 
3.6.2.2. Transcription Factors analysis 
 
Importantly, changes in the primary DNA sequence have been associated with 
differences in gene expression and TF binding between human individuals (Kasowski, 
Grubert et al. 2010). Those alterations can be heritable, so they can contribute to 
phenotypic variation within FAP patients. This supports the hypothesis that the cis-
regulatory elements of the TTR gene modulate the effect of mutations on the disease 
phenotype, including age onset. 
The 3 intronic SNPs already known found in our results are related with new TFBSs 
according to is-rSNP. Among the new TFBSs, TEAD1 and LM6, originated by rs1791228, 
downstream 3’ untranslated region of TTR gene, were already studied.  
LM6 is a RNA motif that is present in genes encoding histone proteins and is responsible 
for mRNA folding into a stem-loop structure involved in posttranscriptional regulation, 
including 3’-end processing of histone pre-mRNAs (Xie, Mikkelsen et al. 2007).The 3’ end 
of histone mRNA is formed by an endonucleolytic cleavage after a conserved stem-loop 
sequence of the primary transcript. The cleavage reaction, besides the stem-loop binding 
protein, which binds the stem-loop sequence, requires the U7 snRNP that interacts with a 
sequence downstream from the cleavage site (Harris, Bohni et al. 1991, Dominski, Zheng 
et al. 1999).  Therefore LM6 plays a critical role in histone levels. Expression of histone 
genes is cell-cycle-regulated, and histone mRNAs are present at high levels during S-phase, 
related with high transcription levels (Dominski and Marzluff 1999). This high transcription 
levels include all the cell genome, including TTR gene. Possibly this new TFBS can be related 
with an increase in transcription levels and with high levels of TTR, which could lead to an 
anticipation of the disease onset. 
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TEAD-1 is a TF involved in activation of promoters of muscle-related genes, such as the 
cardiac muscle troponin T gene, skeletal muscle actin and myosin heavy chains genes 
(Zhou, Licklider et al. 2002). V30M haplotype may carry the non-coding variant rs1791228 
with involvement in cardiac function, explaining partially the cardiomyopathy associated 
with some carriers of V30M mutation. Polimanti et al had proposed that this non-coding 
variant is related with Val122Ile haplotype, involved the cardiac symptoms predominance 
(Polimanti, Di Girolamo et al. 2013).  
LM201, LM70 and LM103 are other TFs that bind to the genomic regions in which SNPs 
are located. Those TFs were not studied, however they could alter the transcription levels 
of TTR and therefore be involved in FAP phenotype. 
 
3.6.2.3. miRNA analysis 
 
One paramount analysis that is important to take into account and that is being 
intensively studied in another neurodegenerative diseases (Sethupathy and Collins 2008, 
Wang, van der Walt et al. 2008, Laguette, Abrahams et al. 2011, Amin, Giudicessi et al. 
2012) is the possible location of SNPs in miRNA (microRNA) target sites that could modify 
TTR expression affecting ultimately FAP phenotype. 
miRNAs are endogenous small non-coding RNAs that are transcribed from genomic 
sequences, cleaved into miRNA precursors and processed into a mature miRNA with 19-23 
nucleotides (Bartel 2004). miRNA regulates the expression of mRNA either by binding to 
the 3’UTR of a transcript, therefore marking it for degradation, or by binding to the mRNA, 
stopping translation of the protein (Kwak, Iwasaki et al. 2010). 
The presence of miRNA target sites in 3’UTR of TTR gene had already been studied like 
it was cited before (Olsson, Norgren et al. 2010, Norgren, Hellman et al. 2012). In these 
studies performed by Olsson and colleagues (Olsson, Norgren et al. 2010), they used 
different miRNA target prediction programs from those that we used. They used 
MicroInspector and PITA algorithm in both studies to assess miRNA target sites for the SNPs 
identified. They confirmed their results using additionally RNAhybrid and RegRNA. In our 
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study we also used MicroInspector, PITA and RNAhybrid plus the miRWalk software that 
combines the results for more six softwares. 
We concluded that the usage of these programs should be done with a critical view, 
because they can present different results from each other according to the algorithms and 
the thresholds used. To minimize false positive predictions we set up criteria that the 
predicted miRNA targets should fulfil: the miRNA should be present in all the prediction 
softwares we used, be expressed in liver and evolutionary conserved between species. 
We found two miRNAs with predicted target sites for the WT (C) allele of rs62093482 
(hsa-mir-200a and has-mir-141) and both expressed in liver and well conserved between 
species (Li, Chen et al. 2009, Yin, Bai et al. 2014). The polymorphic allele (T) of rs62093482 
does not interfere with the hsa-mir-200a and hsa-mir-141 binding to the putative target 
sites, so that, from what we can concluded that they are not involved in AO variability of 
FAP. 
Importantly, the miRNAs with putative target sites in the polymorphic allele (T) of 
rs62093482 are hsa-mir-1279 and hsa-mir-622. The hsa-mir-1279 has not hepatic 
expression, therefore we excluded the implication of this miRNA putative target site in AO 
variation of FAP. The hsa-mir-622 is expressed in liver and well conserved between species. 
Olsson et al (Olsson, Norgren et al. 2010) proposed that the 3’UTR polymorphism 
rs62093482, also present in Swedish TTR V30M carriers, can served as a miRNA binding site 
to hsa-mir-622, possibly leading to a down regulation of mutant TTR expression, explaining 
the low penetrance and an increase in AO of disease observed in the Swedish patient 
population. However, posterior analysis in vitro to evaluate the exposed possibility this 
hypothesis showed that the rs62093482 of the TTR gene has no effect on degrading the 
variant allele’s expression and thus has no impact on the diminished penetrance of the 
Swedish patients. They noted that the ratio of mutated to wild type TTR in plasma was 
approximately the same in Swedish and Portuguese FAP patients (40% to 60%), so that they 
concluded the hsa-mir-622 does not interfere with protein translation, is non-functional 
and is not involved in FAP AO variability. 
We studied another polymorphism in 3’UTR of TTR gene that was found in one patient: 
c.*75A>C. When the C allele of this new polymorphism is present, we observed that 5 
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miRNAs predicted target sites are created: hsa-mir-1279, hsa-mir-622, hsa-mir-1250, hsa-
mir-1267 and hsa-mir-138. For the same reason explained above, we concluded hsa-mir-
622 and hsa-mir-1279 are not involved in FAP AO. The miRNAs hsa-mir-1250 and hsa-mir-
1267 are not expressed in liver and are poorly conserved between species, so they do not 
fulfill the criteria that we defined. 
After a BLAST analysis, we confirmed that this region is conserved in several species 
(including non-mammals) and importantly mir-138 is expressed in the liver reinforcing the 
hypothesis that mir-138 should be studied in vivo in order to confirm these results and to 
increase the hypothesis that this miRNA might play a role in TTR mechanisms of AO 
variation (Eskildsen, Taipaleenmaki et al. 2011). 
Recently, several studies have reported that differential expression of miRNAs, including 
mir-138, are implicated in neurodegenerative disorders, like Alzheimer’s Disease, 
Huntington’s Disease, schizophrenia and bipolar disease. It was demonstrated that mir-138 
is upregulated in the brains of Alzheimer’s patients. This involvement of miRNAs in 
neurodegenerative disorder point to a possible therapeutic value of these molecules. 
The two SNPs of TTR 3’UTR we have studied are not present in the same patient, but if 
it happens, it is important to think about the synergic effect of miRNA putative target sites 
of both. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CONCLUDING REMARKS 
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This study aimed to identify possible genetic modifiers within the TTR gene. After 
genotyping a large number of individuals (230 patients) we found some interesting variants 
that required our attention. We found 8 SNPs in our sample, 3 previously undescribed and 
5 already identified.  
 A previously described polymorphism rs1800458 (Ser6) is a benign SNP regarding 
protein function and it is related with an increased TTR thyroxine-binding affinity; 
 rs28933981 (Thr119Met) although probably damaging for protein function seems 
to be related with a protective effect against amilodogenecity; 
 We found a new acceptor site related with rs1800458 and a stronger branch point 
with rs1791228, with probability to alter splicing activity on TTR gene; 
 rs28933981 disrupts 4 ESEs, which may lead to protein disruption effect and to a 
translation of a TTR tagged to be degraded, decreasing fibrils formation; 
 We found 5 new TFBSs related with rs36204272, rs1791228 and rs62093482. Two 
of these TFBSs were already studied: LM6 and TEAD1; 
 LM6 may be related with an increased in transcription levels and TEAD1 with cardiac 
manifestations of FAP; 
 We found hsa-mir-138, a miRNA related with c.*75A>C, with an already stablished 
relationship with neurodegenerative disorders, and a possible object of future 
studies in FAP area; 
 Importantly, the possible miRNA binding to TTR WT, confirmed by 8 algorithms. 
Although none of these findings were significantly related with AO, our results open new 
perspectives that deserve to be further explored since our bioinformatic analysis revealed 
putative mechanisms of regulation of gene expression within the TTR gene that could be 
used in the future as potential therapeutical targets. 
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 Increase our sample to draw conclusions about the presence of rare polymorphisms 
and its effect on AO of disease, including the new polymorphisms identified, and to 
understand if the new SNPs found are exclusive of the Portuguese population;  
  Study the possible relation between the presence of rs1791228, the new TFBSs for 
TEAD-1 and the prevalence of cardiac symptoms; 
 Confirm with in vivo studies the presence of the new TFBSs for TEAD-1 in carriers of 
rs1791228 and a possible effect on mRNA expression; 
 Confirm with in vivo studies the miRNAs binding with WT TTR (mir-200a and mir-
141);  
 Study the possible presence of c.*75A>C in more V30M TTR carriers and study the 
association of the putative target site for mir138 with the phenotype; 
 Apply the information about TTR mRNA splicing alterations in therapeutics, like 
antisense oligonucleotides; 
 Perform a SNP profile for TTR gene in livers in patients already transplanted to 
understand the differences in disease progression found in this patients; 
 Study the prevalence of renal and cardiac symptoms and its relation with the SNPs 
found. 
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Table 1: Primers sequence (Fw-forward; Rv-reverse). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: PCR amplification mixture reagents. 
 
 
 
 
 
 
 
 
Foward or Reverse Primer Sequence 
Exon 1 – primer Fw CCAAGAATGTTAGTGCACGCAGTC 
Exon 1 – primer Rv  TCAGAGTTCAAGTCCCAGCTCAGT 
Exon 2 – primer Fw ACGTCTGTGTTATACTGAGTAGGG 
Exon 2 – primer Rv ATGCTCAGGTTCCTGGTCACTT 
Exon 3 – primer Fw CAGCCTGGGTGACAAGAGTA 
Exon 3 – primer Rv TTATTTCAACAGCAGATACATCAAT 
Exon 4 – primer Fw TTCCGGTGGTCAGTCATGTG 
Exon 4 – primer Rv GCCCACAGTAAAGAAGTGGG 
Reagents Volume/Reaction (µL) 
DNA template ([10 ng/µL]) 2 
Primer Fw 10µM 1.50 
Primer Rev 10µM 1.50 
HotStar Master Mix 6.25 
H2O 1.25 
Total 12.50 
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Table 3: PCR conditions for the four exon of TTR gene (exon 3 with annealing temperature at 56oC and the remaining 
at 58oC). 
 
 
Table 4: PCR products purification components. 
 
Table 5: PCR products purification conditions. 
 
 
 
 
 
 
  
Number of Cycles Temperature Time Phases 
1 95oC 15 min Initial Denaturation 
 95oC 45 sec Denaturation 
30 56/58oC 1 min Annealing 
 72oC 1 min Extension 
1 72oC 10 min Final Extension 
- 4oC ∞  
Components Volume/Reaction (µL) 
PCR product 2 
ExoStar 0.5 
Total 2.50 
Temperature Time Phases 
37oC 15 min Enzymatic Digestion 
85oC 15 min Enzymatic Inactivation 
4oC ∞  
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Table 6: Sequencing mixture components. 
 
 
Table 7: Cycle sequencing conditions program. 
 
 
 
 
 
 
 
 
 
 
 
Components Volume/Reaction (µL) 
Purified PCR product  2.50 
H2O 5.00 
Primer (Fw/Rv) 0.50 
Premix BigDye® Terminator v1.1 – 1:1 2.00 
Total 10.00 
Number of Cycles Temperature Time 
1 95oC 5 min 
 96oC 10 sec 
35 50oC 5 sec 
 60oC 4 min 
- 4oC ∞ 
